A new perspective to improve the treatment of Lianhuaqingwen on COVID-19 and prevent the environmental health risk of medication

Abstract

Lianhuaqingwen (LH), one traditional Chinese medicine (TCM), has been used to treat the coronavirus disease 2019 (COVID-19), but its ecotoxicity with potential human health security has not been well investigated. To overcome such adverse effects and improve its medication efficacy, an intelligent multi-method integrated dietary scheme, screening, and performance evaluation approach was developed. Thirteen LH compounds were selected, and the main protease (Mpro) was used as the potential drug target. Resulted information showed that the more compounds of LH added, the higher medication efficacy obtained using multi-method integrated screening system, expert consultation method, and molecular dynamics simulation. Pharmacodynamic mechanism analysis showed that low total energy and polar surface area of LH active compound (i.e., β-sitosterol) will contribute to the best therapeutic effect on COVID-19 using quantitative structure-activity relationships (QSAR) and sensitivity models. Additionally, when mild COVID-19 patients take LH with the optimum dietary scheme (i.e., β-lactoglobulin, α-lactalbumin, vitamin A, vitamin B, vitamin C, carotene, and vitamin E), the medication efficacy were significantly improved (23.58%). Pharmacokinetics and toxicokinetics results showed that LH had certain human health risks and ecotoxicity. This study revealed the multi-compound interaction mechanism of LH treatment on COVID-19, and provided theoretical guidance for improving therapeutic effect, evaluating TCM safety, and preventing human health risk. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s11356-022-21125-w.

Association of dietary intake of polyphenols, lignans, and phytosterols with immune-stimulating microbiota and COVID-19 risk in a group of Polish men and women

“…However, the antiviral efficacy of polyphenols including lignans and plant sterols has been confirmed against SARS-CoV, MERS-CoV, Ebola virus, HIV, influenza virus and other viruses causing respiratory tract infections (18)(19)(20)(21). Recent studies have also demonstrated their beneficial effects against the SARS-CoV-2 virus (18,(22)(23)(24) resulting from their ability to bind to peak protein sites on the ACE2 receptor used by SARS-CoV-2 to infect cells (25, 26), regulate ACE2 expression and also interfere with SARS-CoV-2 replication by inhibiting the virus protease or inhibiting SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) (27,28). The antiviral activity of some of them is comparable to or stronger than pharmacological agents (naringenin, vs. remdesivir (29), citrus flavonoids and polyphenols from Curcuma spp.…”

A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants

“…Inflammatory storm is a systemic inflammatory response triggered by various factors, including infection and drugs, and is characterized by a sharp increase in the levels of a large number of pro-inflammatory cytokines. Evidence from a wide range of sources suggests that SARS-CoV-2 infection induces an excessive inflammatory response and cytokine storm (CS), and CS is a vital factor in the conversion of patients with COVID-19 from mild to severe and critical illness (Gu et al, 2022). After infection with SARS-COV-2, the innate immune system is triggered, and various inflammatory pathways are activated, among which NLRP/IL-1β, JAK/STAT, TNF-α/NF-κB, and other pathways have been confirmed to be closely related to SARS-CoV-2 infection (Jiang et al, 2020).…”

Extraction, Purification, Structural Characteristics, Health Benefits, and Application of the Polysaccharides from Lonicera japonica Thunb.: A Review

“…Lianhua Qingwen, a Chinese patent medicine containing L. japonica , has good antiviral, immunomodulatory, and anti-inflammatory activities. It has been prescribed for the prevention and treatment of coronavirus infections [ 98 ]. According to the performance report of Lianhua Qingwen’s manufacturer Yiling Pharmaceutical, in 2022, it is expected to achieve net profit of CNY 21.5 to 24.19 billion, an increase of 60% to 80% over the same period last year, and its highest net profit has been close to the sum of 2020 and 2021.…”